Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Influenza vaccine surface antigen, inactivated, is an **inactivated viral vaccine** used for the **prevention of influenza** disease caused by various influenza A and B virus subtypes contained in the vaccine[1][2][4]. It contains surface antigens—**hemagglutinin (HA) and neuraminidase (NA)**—purified from influenza viruses that have been inactivated, often with an adjuvant like MF59 (squalene oil-in-water emulsion) in some formulations. The vaccine stimulates the immune system to produce antibodies against HA and NA, which neutralize and prevent cell entry of the influenza virus, providing active immunization[3][1][4]. It does not contain live viruses and cannot cause influenza[2][3]. Developed according to World Health Organization recommendations, strain composition is updated yearly to match circulating strains[1][2][4]. The main use is **seasonal influenza prophylaxis** in children, adults, and older adults, with specific products indicated for certain age groups[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on influenza vaccine surface antigen, inactivated.